Glutamate, Dopamine, and Schizophrenia from Pathophysiology to Treatment

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 138-158

  Laruelle, Marc ^a   Kegeles, Lawrence S ^a   Abi Dargham, Anissa ^a  

^a Columbia Univ Coll of Phys Surgs ^*  (United States)

Author keywords

Dopamine; Glutamate; PET; Schizophrenia; SPECT

Indexed keywords

4 AMINOBUTYRIC ACID; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DOPA; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; EGLUMETAD; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; PHENCYCLIDINE; RACLOPRIDE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN RECEPTOR;

BINDING AFFINITY; BRAIN CORTEX; BRAIN FUNCTION; CHEMICAL INTERACTION; CONFERENCE PAPER; CORPUS STRIATUM; DEPRESSION; DISEASE ASSOCIATION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG POTENCY; GABAERGIC SYSTEM; HOMEOSTASIS; HUMAN; HYPOTHESIS; MOLECULAR BIOLOGY; NEGATIVE SYNDROME; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PLASTICITY; POSITIVE SYNDROME; PREFRONTAL CORTEX; REGULATORY MECHANISM; SCHIZOPHRENIA; STIMULATION; SYNAPSE;

ANIMALIA;

EID: 0347091932     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.063     Document Type: Conference Paper

References (134)

1. CARLSSON, A. & M. LINDQVIST. 1963. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20: 140-144.
2. SEEMAN, P. & T. LEE. 1975. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188: 1217-1219.
3. CREESE, I., D.R. BURT & S.H. SNYDER. 1976. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 19: 481-483.
4. LIEBERMAN, J.A., J.M. KANE & J. ALVIR. 1987. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91: 415-433.
5. ANGRIST, B. & D.P. VAN KAMMEN. 1984. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci. 7: 388-390.
6. KNABLE, M.B. & D.R. WEINBERGER. 1997. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11: 123-131.
7. GOLDMAN-RAKIC, P.S., E.C. MULY, 3RD & G.V. WILLIAMS. 2000. D(1) receptors in prefrontal cells and circuits. Brain Res. Brain Res. Rev. 31: 295-301.
8. DAVIS, K.L. et al. 1991. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148: 1474-1486.
9. WEINBERGER, D.R. 1987. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44: 660-669.
10. OLNEY, J.W. & N.B. FARBER. 1995. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52: 998-1007.
11. JAVITT, D.C. & S.R. ZUKIN. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148: 1301-1308.
12. TAMMINGA, C.A. et al. 1995. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int. Clin. Psychopharmacol. 3: 29-37.
13. GOFF, D.C. & J.T. COYLE. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158: 1367-1377.
14. JENTSCH, J.D. & R.H. ROTH. 1999. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225.
15. MILLER, D.W. & E.D. ABERCROMBIE. 1996. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull. 40: 57-62.
16. KEGELES, L.S. et al. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 48: 627-640.
17. REITH, J. et al. 1994. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA 91: 11651-11654.
18. HIETALA, J. et al. 1995. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346: 1130-1131.
19. DAO-CASTELLANA, M.H. et al. 1997. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Res. 23: 167-174.
20. HIETALA, J. et al. 1999. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophrenia Res. 35: 41-50.
21. MEYER-LINDENBERG, A. et al. 2002. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5: 267-271.
22. LINDSTROM, L.H. et al. 1999. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol. Psychiatry 46: 681-688.
23. LARUELLE, M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20: 423-451.
24. LARUELLE, M. et al. 1997. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1-14.
25. BREIER, A. et al. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 94: 2569-2574.
26. KEGELES, L.S. et al. 1999. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31: 302-308.
27. PICCINI, P., N. PAVESE & D.J. BROOKS. 2003. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann. Neurol. 53: 647-653.
28. VILLEMAGNE, V.L. et al. 1999. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 33: 268-273.
29. LARUELLE, M. et al. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc. Natl. Acad. Sci. USA 93: 9235-9240.
30. ABI-DARGHAM, A. et al. 1998. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155: 761-767.
31. LARUELLE, M. et al. 1999. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 46: 56-72.
32. LARUELLE, M. 1999. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res. Rev. In press.
33. DEUTCH, A.Y., W.A. CLARK & R.H. ROTH. 1990. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521: 311-315.
34. KALIVAS, P.W. & P. DUFFY. 1995. Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675: 325-328.
35. PARSEY, R.V. et al. 2001. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol. Psychiatry 50: 313-322.
36. 2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA 97: 8104-8109.
37. WEINBERGER, D.R., K.F. BERMAN & T.N. CHASE. 1988. Mesocortical dopaminergic function and human cognition. Ann. NY Acad. Sci. 537: 330-338.
38. KAHN, R.S. et al. 1994. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr. Res. 11: 217-224.
39. DANIEL D.G. et al. 1991. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 11: 1907-1917.
40. DOLAN, R.J. et al. 1995. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378: 180-182.
41. AKIL, M. et al. 1999. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 156: 1580-1589.
42. 1 receptors using positron emission tomography. Appl. Radiat. Isot. 37: 1039-1043.
43. LARUELLE, M. et al. 1991. Characterization of [125I]SCH23982 binding in human brain: comparison with [3H]SCH23390. Neurosci. Lett. 31: 273-276.
44. 1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl). 106: 14-18.
45. 1 receptor antagonists. Eur. J. Pharmacol. 219: 45-52.
46. 1-dopamine receptors. J. Nucl. Med. 39: 2061-2068.
47. 1 radiotracer [11C]NNC 756. Synapse 32: 93-109.
48. 1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J. Cereb. Blood Flow Metab. 20: 225-243.
49. 1 receptors in schizophrenia revealed by PET. Nature 385: 634-636.
50. KARLSSON, P. et al. 2002. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am. J. Psychiatry 159: 761-767.
51. 1 receptors and working memory in schizophrenia. J. Neurosci. 22: 3708-3719.
52. 1 ligand binding in rodent brain. Soc. Neurosc. Abst. 27.
53. PYCOCK, C.J., R.W. KERWIN & C.J. CARTER. 1980. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286: 74-77.
54. KOLACHANA, B.S. et al. 1996. Abnormal prefrontal cortical regulation of striatal dopamine release after neonatal medial temporal-limbic lesions in rhesus monkeys. Soc. Neurosci. Abst. 22: 1974.
55. KRYSTAL, J.H. et al. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51: 199-214.
56. LAHTI, A.C. et al. 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
57. LAHTI, A.C. et al. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
58. JAVITT, D.C. et al. 1994. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151: 1234-1236.
59. JAVITT, D.C. et al. 2001. Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 4: 385-391.
60. HERESCO-LEVY, U. et al. 1999. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56: 29-36.
61. HERESCO-LEVY, U. et al. 1998. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int. J. Neuropsychopharmcol. 1: 131-135.
62. HERESCO-LEVY, U. et al. 2002. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159: 480-482.
63. GOFF, D.C. et al. 1999. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56: 21-27.
64. TSAI, G. et al. 1998. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44: 1081-1089.
65. MILLAN, M.J. 2002. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr. Drug Target CNS Neurol. Disord. 1: 191-213.
66. HARRISON, P.J. 1999. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593-624.
67. MEADOR-WOODRUFF, J.H. & D.J. HEALY. 2000. Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev. 31: 288-294.
68. KONRADI, C. & S. HECKERS. 2003. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol. Ther. 97: 153-179.
69. FRANKLE, W.G., J. LERMA & M. LARUELLE. 2003. The synaptic hypothesis of schizophrenia. Neuron 39: 205-216.
70. CARLSSON, A., N. WATERS & M.L. CARLSSON. 1999. Neurotransmitter interactions in schizophrenia - therapeutic implications. Biol. Psychiatry 46: 1388-1395.
71. CARR, D.B. & S.R. SESACK. 2000. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J. Neurosci. 20: 3864-3873.
72. JACKSON, M.E., A.S. FROST & B. MOGHADDAM. 2001. Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens. J. Neurochem. 78: 920-923.
73. TAKAHATA, R. & B. MOGHADDAM. 2000. Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area. J. Neurochem. 75: 1775-1778.
74. ADAMS, B.W., C.W. BRADBERRY & B. MOGHADDAM. 2002. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse 43: 12-18.
75. KEGELES, L.S. et al. 2002. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43: 19-29.
76. 2 receptor binding in man. Psychopharmacology (Berl). 164: 401-406.
77. BREIER, A. et al. 1998. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29: 142-147.
78. SMITH, G.S. et al. 1998. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18: 18-25.
79. VOLLENWEIDER, F.X. et al. 2000. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J. Psychiatr. Res. 34: 35-43.
80. BUNNEY, B.S. & G.K. AGHAJANIAN. 1978. d-Amphetamine-induced depression of central dopamine neurons: evidence for mediation by both autoreceptors and a striatonigral feedback pathway. Naunyn Schmiedebergs Arch. Pharmacol. 304: 255-261.
81. MOGHADDAM, B. et al. 1997. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17: 2921-2927.
82. MOGHADDAM, B. & B.W. ADAMS. 1998. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
83. PIN, J P. et al. 1999. New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur. J. Pharmacol. 375: 277-294.
84. NAKANISHI, S. & M. MASU. 1994. Molecular diversity and functions of glutamate receptors. Annu. Rev. Biophys. Biomol. Struct. 23: 319-348.
85. SCHOEPP, D.D. 2002. Metabotropic glutamate receptors. Pharmacol. Biochem. Behav. 73: 285-286.
86. EAST, S.J., M.P. HILL & J.M. BROTCHIE. 1995. Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. Eur. J. Pharmacol. 277: 117-1121.
87. BATTAGLIA, G., J.A. MONN & D.D. SCHOEPP. 1997. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett. 229: 161-164.
88. DI IORIO, P. et al. 1996. Interaction between A1 adenosine and class II metabotropic glutamate receptors in the regulation of purine and glutamate release from rat hippocampal slices. J. Neurochem. 67: 302-309.
89. SCHOEPP, D.D. et al. 1997. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology 36: 1-11.
90. VAN BERCKEL, B.N.M. et al. 2001. Enhanced amphetamine-induced striatal [11C]raclopride displacement by the group II metabotropic glutamate receptor agonist L354740 in baboons. Soc. Neurosci. Abst. 454.3.
91. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19: 264-293.
92. SMITH, A.D. & J.P. BOLAM. 1990. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13: 259-265.
93. KOTTER, R. 1994. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44: 163-196.
94. NICOLA, S.M., J. SURMEIER & R.C. MALENKA. 2000. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu. Rev. Neurosci. 23: 185-215.
95. CEPEDA, C. & M.S. LEVINE. 1998. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20: 1-18.
96. LEVINE, M.S. et al. 1996. Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 24: 65-78.
97. CENTONZE, D. et al. 2001. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur. J. Neurosci. 13: 1071-1077.
98. 2 dopamine receptor-deficient mice. J. Neurophysiol. 85: 659-670.
99. PERIS, J., L.P. DWOSKIN & N.R. ZAHNISER. 1988. Biphasic modulation of evoked [3H]D-aspartate release by D-2 dopamine receptors in rat striatal slices. Synapse 2: 450-456.
100. LEVEQUE, J.C. et al. 2000. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20: 4011-4220.
101. ONN, S.P., A.R. WEST & A.A. GRACE. 2000. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci. 23: S48-56.
102. 2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci. 22: 294-304.
103. 2 receptors. J. Neurochem. 83: 635-644.
104. 2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. Eur. J. Pharmacol. 256: 23-30.
105. 2+ conductance. J. Neurosci. 17: 3334-3342.
106. 1 receptors and DARPP-32. J. Neurophysiol. 88: 3010-3020.
107. WILSON, C.J. & Y. KAWAGUCHI. 1996. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J. Neurosci. 16: 2397-2410.
108. 1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21: 5546-5558.
109. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl). 121: 309-316.
110. 1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl.) 121: 328-329.
111. 1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl.) 121: 323-327.
112. 1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl.) 121: 317-322.
113. 2 receptors in dopamine depleted animals. Psychopharmacology (Berl.) 135: 311-317.
114. 2 receptors? Psychopharmacology (Berl.) 138: 213-216.
115. 1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol. Toxicol. 84: 193-196.
116. GRACE, A.A. 1992. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J. Neural Transm. Suppl. 36: 91-131.
117. GRACE, A.A. et al. 1997. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 20: 31-37.
118. MELTZER, H.Y. 1991. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17: 263-287.
119. MRZLETAK, L. et al. 1996. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 381: 245-248.
120. 1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc. Natl. Acad. Sci. USA 91: 5720-5724.
121. YANG, C.R., J.K. SEAMANS & N. GORELOVA. 1999. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21: 161-194.
122. DEL ARCO, A. & F. MORA. 2000. Endogenous dopamine potentiates the effects of glutamate on extracellular GABA in the prefrontal cortex of the freely moving rat. Brain Res. Bull. 53: 339-345.
123. GROBIN, A.C. & A.Y. DEUTCH. 1998. Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat. J. Pharmacol. Exp. Ther. 285: 350-357.
124. SEAMANS, J.K. et al. 2001. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 21: 3628-3638.
125. GORELOVA, N., J.K. SEAMANS & C.R. YANG. 2002. Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. J. Neurophysiol. 88: 3150-3166.
126. 1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc. Natl. Acad. Sci. USA 98: 301-306.
127. FIENBERG, A. et al. 1998. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281: 838-842.
128. SEAMANS, J.K. et al. 2001. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 21: 3628-3638.
129. WESTERINK, B.H. et al. 2001. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412: 127-138.
130. ICHIKAWA, J. et al. 2001. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76: 1521-1531.
131. GESSA, G.L. et al. 2000. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22: 642-649.
132. YOUNGREN, K.D. et al. 1999. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20: 403-412.
133. ROLLEMA, H. et al. 1997. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol. 338: R3-5.
134. YAMAMOTO, B.K. & M.A. COOPERMAN. 1994. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14: 4159-4166.